大分割术后乳房放疗研究综述
本文综述了支持大分割术后乳房放疗(PMRT)治疗局部晚期乳腺癌的主要随机试验。标准分割仍是最常用方案,但近期发表的试验支持大分割方案的安全性和有效性,正在进行的试验将进一步研究大分割PMRT。
要点
- 标准分割(5-7周)仍是PMRT的常用方案。
- 近期试验支持大分割PMRT的安全性和有效性。
- 正在进行的试验进一步研究大分割PMRT。
核心结论
- 标准分割仍是PMRT最常用的方案,但近期发表的试验支持大分割方案的安全性和有效性。
- 正在进行的试验将进一步研究大分割PMRT的应用。
研究设计与样本
- 通过系统综述PubMed中报告大分割放疗用于需要PMRT患者的出版物,概述支持大分割PMRT的主要随机试验。
主要发现
- 现代数据已帮助确立大分割全乳放疗(3-4周方案)作为早期乳腺癌的新标准治疗。
- 大分割全乳放疗为大分割PMRT的探索奠定了基础。
临床怎么用
- 标准分割(5-7周)仍被视为PMRT的标准治疗。
- 大分割全乳放疗(3-4周方案)是早期乳腺癌的新标准治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To provide an overview of the major randomized trials that support the use of hypofractionated post-mastectomy radiation therapy for locally advanced breast cancer patients. METHODS AND MATERIALS: PubMed was systematically reviewed for publications reporting use of of hypofractionated radiation therapy in patients requiring post-mastectomy radiation. RESULTS: Standard fractionation, which is typically delivered over 5 to 7 weeks, is considered the standard of care in setting of post-mastectomy radiation therapy (PMRT). Modern data has helped to establish hypofractionated whole breast irradiation, which consists of a 3- to 4-week regimen, as a new standard of care for early-stage breast cancer. Hypofractionated whole breast irradiation has also laid the groundwork for the exploration of a hypofractionated approach in the setting of hypofractionated post-mastectomy radiation therapy. CONCLUSIONS: While standard fractionation remains the most commonly utilized regimen for PMRT, recently published trials support the safety and efficacy of a hypofractionated approach. Ongoing trials are further investigating the use of hypofractionated PMRT.
引用
- Sayan M, Yehia ZA, Ohri N, et al. Hypofractionated Postmastectomy Radiation Therapy. Adv Radiat Oncol. 2020. PMID: 33490735. doi:10.1016/j.adro.2020.11.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。